Newcastle University

Research Interests

I am a proteinase biochemist with interests in the molecular mechanisms that regulate the enzymic activity that mediates tissue destruction as well as the signal transduction events that lead to the transcriptional activation of those proteinase genes. My work is focussed on extracellular matrix remodelling events during pathology, with a particular emphasis within the setting of inflammatory joint diseases.

• Ciechomska M, Wilson CL, Hui W, Rowan AD, Robinson JH, Knight AM. Aggrecan-specific B lymphocytes acquire native autoantigen from cartilage extracellular matrix: implications for the role of B cells as antigen presenting cells in Rheumatoid Arthritis. 2013. In Preparation.
• Radwan M, Gavriilidis C, Robinson JH, Davidson R, Clark IM, Rowan AD, Young DA. Matrix metalloproteinase-13 expression in response to double-stranded RNA in human chondrocytes. Arthritis and Rheumatism 2013, (epub ahead of print).
• Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, Rowan AD, Young DA. cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. FASEB Journal 2012, 26(7), 3000-3011.
• Xu Y, Barter MJ, Swan DC, Rankin KS, Rowan AD, Santibanez-Koref M, Lo Ighlin J, Young DA. Comparison of osteoarthritis and normal hip cartilage transcriptomes using RNA-seq reveals new candidate gene targets and associated pathways. In: World Congress on Osteoarthritis. 2012, Barcelona, Spain: Elsevier Ltd.
• Litherland GJ, Elias MS, Curtis H, Rowan AD. Glycogen synthase kinase-3 as a gatekeeper of human cartilage degradation. In: Autumn Meeting of the British Society for Matrix Biology (BSMB). 2012, Newcastle upon Tyne, UK: Wiley-Blackwell Publishing Ltd.
• Macdonald CDM, Rowan AD, Europe-Finner N. Identification of synergistic transcriptional regulation for collagenase gene expression in chondrocytes. In: Autumn Meeting of the British Society for Matrix Biology (BSMB). 2012, Newcastle upon Tyne, UK: Wiley-Blackwell Publishing Ltd.
• Xu Y, Barter MJ, Swan DC, Rankin KS, Rowan AD, Santibanez-Koref M, Loughlin J, Young DA. Identification of the pathogenic pathways in osteoarthritic hip cartilage: commonality and discord between hip and knee OA. Osteoarthritis and Cartilage 2012, 20(9), 1029-1038.
• Radwan MA, Gabrielides C, Rowan AD, Robinson JH, Cawston TE, Young DA. Involvement of pattern recognition receptors in poly(I:C)-mediated MMP-13 expression. In: Autumn Meeting of the British Society for Matrix Biology (BSMB). 2012, Newcastle upon Tyne, UK: Wiley-Blackwell Publishing Ltd.
• Hui W, Litherland GJ, Elias MS, Kitson GI, Cawston TE, Rowan AD, Young DA. Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Annals of the Rheumatic Diseases 2012, 71(3), 455-462.
• Goff I, Rowan A, Bateman BJ, Foster HE. Poor sensitivity of musculoskeletal history in children. Archives of Disease in Childhood 2012, 97(7), 644-646.
• Goff I, Rowan A, Bateman B, Foster HE. Poor sensitivity of musculoskeletal history in children. Archives of Disease in Childhood 2012, 97(7), 644-646.
• Ciechomska M, Wilson C, Rowan A, Robinson JH, Knight AM. Antigen-specific B cells can acquire and present the rheumatoid arthritis candidate autoantigen aggrecan from a non-internalisable surface. In: Annals of the Rheumatic Diseases: 31st European Workshop for Rheumatology Research. 2011, Amsterdam, Netherlands: BMJ Group.
• Zheng J, Rowan AD, Lilic D. Effect of cytokine-induced STAT1 signaling on STAT3 activation and binding. In: Immunology: Annual Congress of the British Society for Immunology. 2011, Liverpool, UK: Wiley-Blackwell Publishing Ltd.
• Cawston TE, Lakey RL, Rowan AD. Assay of matrix metalloproteinases against matrix substrates. In: Clark, IM, ed. Matrix Metalloproteinase Protocols. New York: Humana Press, 2010, pp.245-255.
• Hui W, Litherland GJ, Jefferson M, Barter MJ, Elias MS, Cawston TE, Rowan AD, Young DA. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology 2010, 49(11), 2043-2053.
• Milner JM, Patel A, Davidson RK, Swingler TE, Desilets A, Young DA, Kelso EB, Donell ST, Cawston TE, Clark IM, Ferrell WR, Plevin R, Lockhart JC, Leduc R, Rowan AD. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis & Rheumatism 2010, 62(7), 1955-1966.
• Richards CD, Kerr C, Fritz DK, Rowan AD, Langdon CM. Overexpression of Oncostatin-M in lungs induces eotaxin-2 and eosinophil accumulation in C57BL/6 but not Balb/C mice in vivo. In: Cytokine: 8th Joint Conference of the International Cytokine Society. 2010, Chicago, Illinois, USA: Academic Press.
• Litherland GJ, Elias MS, Hui W, Macdonald CD, Catterall JB, Barter MJ, Farren MJ, Jefferson M, Rowan AD. Protein Kinase C Isoforms zeta and iota Mediate Collagenase Expression and Cartilage Destruction via STAT3-and ERK-dependent c-fos Induction. Journal of Biological Chemistry 2010, 285(29), 22414-22425.
• Lakey RL, Morgan TG, Rowan AD, Isaacs JD, Cawston TE, Hilkens CM. A novel paradigm for dendritic cells as effectors of cartilage destruction. Rheumatology 2009, 48(5), 502-7.
• Hui W, Young DA, Rowan AD, Cawston T. Lithium inhibits cartilage degradation and MMP production induced by pro-inflammatory cytokines. In: International Journal of Experimental Pathology: Annual General Meeting of the British Society for Matrix Biology. 2009, York, UK: Wiley-Blackwell Publishing Ltd.
• Richards CD, Kerr C, Fritz DK, Rowan AD, Langdon CM. Differential responses to oncostatin-M in C57BL/6 and BALB/C mice in vivo. In: Cytokine: 7th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research. 2008, Montreal, Cananda: Academic Press.
• Zhang Q, Hui W, Litherland GJ, Barter MJ, Davidson R, Darrah C, Donell ST, Clark IM, Cawston TE, Robinson JH, Rowan AD, Young DA. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Annals of the Rheumatic Diseases 2008, 67(11), 1633-41.
• Milner JM, Patel A, Rowan AD. Emerging Roles of Serine Proteinases in Tissue Turnover in Arthritis. Arthritis & Rheumatism 2008, 58(12), 3644-3656.
• Rowan AD, Litherland GJ, Hui W, Milner JM. Metalloproteases as potential therapeutic targets in arthritis treatment. Expert Opinion on Therapeutic Targets 2008, 12(1), 1-18.
• Farren M, Jefferson M, Rowan A. STATs and c-fos are critical for synergistic MMP-1 induction in chondrocytes. In: Autumn Meeting of the British Society for Matrix Biology. 2008, Keele University: International Journal of Experimental Pathology, Wiley-Blackwell Publishing Ltd.
• Litherland GJ, Dixon C, Lakey RL, Robson T, Jones D, Young DA, Cawston TE, Rowan AD. Synergistic collagenase expression and cartilage collagenolysis are phosphatidylinositol 3'-kinase/AKT signalling-dependent. Journal of Biological Chemistry 2008, 283(21), 14221-14229.
• Bigg HF, Rowan AD, Barker MD, Cawston TE. Activity of matrix metalloproteinase-9 against native collagen types I and III. The FEBS Journal 2007, 274(5), 1246-1255.
• Rowan AD, Young DA. Collagenase gene regulation by pro-inflammatory cytokines in cartilage. Frontiers in Bioscience 2007, 12(2), 536-550.
• Peake NJ, Foster HE, Khawaja K, Cawston TE, Rowan AD. Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography. Annals of the Rheumatic Diseases 2006, 65(4), 501-507.
• Catterall JB, Rowan AD, Sarsfield S, Saklatvala J, Wait R, Cawston TE. Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatology 2006, 45(9), 1101-1109.
• Milner JM, Kevorkian L, Jones D, Young D, Wait R, Cravatt B, Clark IM, Rowan AD, Cawston TE. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Research & Therapy 2006, 8(1), R23-30.
• Milner JM, Kevorkian L, Young DA, Jones D, Wait R, Donell ST, Barksby HE, Patterson AM, Middleton JM, Cravatt BF, Clark IM, Rowan AD, Cawston TE. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Research & Therapy 2006, 8(1), R23.
• Milner JM, Kevorkian L, Young DA, Jones D, Wait R, Cravatt B, Donell ST, Clark IM, Rowan AD, Cawston TE. Fibroblast-activation protein-alpha is expressed by chondrocytes following a proinflammatory stimulus and is elevated in osteoarthritis. In: International Journal of Experimental Pathology: Autumn Meeting of the British Society for Matrix Biology. 2006, Manchester, UK: Wiley-Blackwell Publishing Ltd.
• Morgan TG, Rowan AD, Dickinson SC, Jones D, Hollander AP, Deehan D, Cawston TE. Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases. Annals of the Rheumatic Diseases 2006, 65(2), 184-190.
• Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, Cawston TE, Rowan AD. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes - Implications for cartilage destruction and repair. Arthritis & Rheumatism 2006, 54(2), 540-550.
• Peake NJ, Khawaja K, Myers A, Nowell MA, Jones SA, Rowan AD, Cawston TE, Foster HE. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 2006, 45(12), 1485-1489.
• Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: Implications for cartilage degradation in arthritis. Arthritis & Rheumatism 2006, 54(10), 3244-3253.
• Milner JM, Rowan AD, Cawston TE, Young DA. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Research & Therapy 2006, 8(5), R142.
• Shingleton WD, Jones D, Xu X, Cawston TE, Rowan AD. Retinoic acid and oncostatin M combine to promote cartilage degradation via matrix metalloproteinase-13 expression in bovine but not human chondrocytes. Rheumatology 2006, 45(8), 958-965.
• Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. Journal of Biological Chemistry 2006, 281(30), 21082-21095.
• Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD, Foster HE. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology 2005, 44(11), 1383-1389.
• Hui W, Barksby HE, Young DA, Cawston TE, McKie N, Rowan AD. Oncostatin M in combination with tumour necrosis factor alpha induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or-2. Annals of the Rheumatic Diseases 2005, 64(11), 1624-1632.
• Hui W, Cawston TE, Richards CD, Rowan AD. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL. Arthritis Research & Therapy 2004, 7(1), R57-R64.
• Rowan AD, Hui W, Cawston TE, Richards CD. Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. The American Journal of Pathology 2003, 162(6), 1975-1984.
• Cawston TE, Milner JM, Catterall JB, Rowan AD. Cytokine synergy, collagenases and cartilage collagen breakdown. Biochemical Society Symposium 2003, 70, 125-133.
• Cawston TE, Milner JM, Catterall JB, Rowan AD. Cytokine synergy, collagenases and cartilage collagen breakdown. In: Biochemical Society Symposia: Proteases and the Regulation of Biological Processes. 2003, London, UK: Portland Press.
• Milner JM, Rowan AD, Elliott SF, Cawston TE. Inhibition of furin-like enzymes blocks interleukin-1 alpha/oncostatin M-stimulated cartilage degradation. Arthritis & Rheumatism 2003, 48(4), 1057-1066.
• Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis & Rheumatism 2003, 48(12), 3404-3418.
• Cawston T, Wang H, Richards C, Rowan A. Synergistic interactions of proinflammatory cytokines with oncostatin M: implications for joint destruction. In: Arthritis Research & Therapy: 3rd World Congress of the Global Arthritis Research Network (GARN). 2003, Miyakazi, Japan: BioMed Central Ltd.
• Hall M-C, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, Clark IM. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. Journal of Biological Chemistry 2003, 278(12), 10304-10313.
• Hui W, Cawston TE, Rowan AD. Transforming growth factor beta 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor alpha from bovine cartilage. Annals of the Rheumatic Diseases 2003, 62(2), 172-174.
• Vaidya B, Pearce SHS, Charlton S, Marshall N, Rowan AD, Griffiths ID, Kendall-Taylor P, Cawston TE, Young-Min S. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 2002, 41(2), 180-183.
• Vaidya B, Pearce SHS, Charlton S, Marshall N, Rowan AD, Griffiths ID, Kendall-Taylor P, Cawston TE, Young Min S. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 2002, 41(2), 180-183.
• Forrest IA, Ward C, Pritchard G, Rowan AD, Cawston TE, Corris PA. Co-localisation of MMP-9 with neutrophils in stable lung transplant recipients - A potential role in Bronchiolitis Obliterans. In: Thorax: Winter Meeting of the British Thoracic Society. 2002, London: BMJ Group.
• Hall MC, Young DA, Rowan AD, Edwards DR, Clark IM. Cryptic promoter activity of pBLCAT3 induced by overexpression of AP1 factors. BioTechniques 2002, 33(5), 1004-+.
• Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Annals of the Rheumatic Diseases 2002, 61(8), 704-713.
• Koshy PJT, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M - A time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis & Rheumatism 2002, 46(4), 961-967.
• Cawston TE, Koshy PJT, Rowan AD. Assays of matrix metalloproteinases against matrix substrates. Methods in Molecular Biology 2001, 151, 389-398.
• Rowan AD. Cartilage catabolism in arthritis; factors that influence homeostasis. Expert Reviews Molecular Medicine 2001, 5 July, http://www-ermm.cbcu.cam.ac.uk / 01003209h.htm.
• Young-Min S, Pearce SHS, Charlton S, Marshall N, Rowan AD, Griffiths ID, Kendall-Taylor P, Cawston TE, Vaidya B. Cytotoxic T lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism in early rheumatoid arthritis. In: RHEUMATOLOGY. 2001, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS.
• Hui W, Rowan A, Cawston T. Insulin-like growth factor 1 blocks collagen release and down regulates matrix metalloproteinase-1, -3, -8, and -13 mRNA expression in bovine nasal cartilage stimulated with oncostatin M in combination with interleukin 1α. Annals of the Rheumatic Diseases 2001, 60(3), 254-261.
• Hui W, Rowan AD, Cawston TE. Insulin-like growth factor-1 blocks the release of collagen fragments from bovine nasal cartilage stimulated by oncostatin M in combination with interleukin-1. Annals Rheumatic Diseases 2001, 60(3), 254-261.
• Cleaver CS, Rowan AD, Cawston TE. Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines. Annals of the Rheumatic Diseases 2001, 60(2), 150-157.
• Cleaver C, Rowan AD, Cawston TE. Interleukin-13 blocks the release of collagen fragments from bovine nasal cartilage treated with proinflammatory cytokines by preventing pro-collagenase activation. Annals Rheumatic Diseases 2001, 60(2), 150-157.
• Cawston TE, Carrere S, Catterall J, Duggleby R, Elliott S, Shingleton WD, Rowan AD. Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronc pulmonary disease. In: Chadwick, D., Goode, J.A, ed. Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment. Chichester: Wiley, 2001, pp.205-228.
• Cawston TE, Carrere SL, Catterall JB, Duggleby RC, Elliott SC, Shingleton B, Rowan AD. Matrix metalloproteinases and TIMPs: Properties and implications for the treatment of chronic obstructive pulmonary disease. In: Novartis Foundation Symposium 234: Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment. 2001, Novartis Foundation, London: Chichester: Wiley.
• Cawston T, Carrere S, Catterall J, Duggleby R, Elliott S, Shingleton B, Rowan A. Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease. In: Symposium on Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment. 2001, London, UK: Wiley-Blackwell.
• Hui W, Rowan AD, Cawston TE. Modulation of the expression of matrix metalloproteinase and tissue inhibitors of metalloproteinases by TGF-beta 1 and IGF-1 in primary human articular and bovine nasal chondrocytes stimulated with TNF-alpha. Cytokine 2001, 16(1), 31-35.
• Hui W, Rowan AD, Cawston T. Modulation of the expression of matrix metalloproteinase and tissue inhibitors of metalloproteinases by transforming growth factor-beta 1 and insulin-like growth factor-1 in primary chondrocytes stimulated with tumour necrosis factor-alpha. In: British Society for Rheumatology XVIII Annual General Meeting and the British Health Professionals in Rheumatology Spring Meeting. 2001, Rheumatology: Oxford University Press.
• Hui W, Rowan AD, Cawston TE. Oncostatin M in combination with TNF synergistically induces expression and production of matrix metaollproteinases and promotes cartlilage breakdown. Arthritis & Rheumatism 2001, 44(Supplement 9), S62 no. 57.
• Rowan AD, Koshy PJT, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, Spaull JR, Life PF, Hudson K, Cawston TE. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis & Rheumatism 2001, 44(7), 1620-1632.
• Catterall JB, Carrere S, Koshy PJT, Degnan BA, Shingleton WD, Brinckerhoff CE, Rutter J, Cawston TE, Rowan AD. Synergistic induction of matrix metalloproteinase 1 by interleukin-1 alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis & Rheumatism 2001, 44(10), 2296-2310.
• Richards CD, Catterall JB, Cawston TE, Rowan AD. Synergistic regulation of chondrocytes by IL-1 and oncostatin M (OSM) involves interaction of JAK/STAT, MAPKinase and c-jun activation. Arthritis & Rheumatism 2001, 44(supplement), S112.
• Bigg HF, Rowan AD. The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Current Opinion in Pharmacology 2001, 1(3), 314-320.
• Rowan AD, Billington CJ, Knight CG, Cawston TE. Cartilage destruction in arthritis: Collagen and aggrecan-degrading proteinases. In: Conference on Tissue Inhibitors of Metalloproteinases in Development and Disease. 2000, Banff, Canada: Harwood Academic Publishers, Gmbh.
• Rowan AD, Billington CJ, Knight CG, Cawston TE. Cartilage destruction in Arthritis: Collagen and Aggrecan-degrading Proteins. In: Tissue inhibitors of metalloproteinases in development and diseases: proceedings of the Inhibitors of Metalloproteinases Conference. 2000, Banff, Canada: Harwood Academic.
• Clark IM, Rowan AD, Cawston TE. Matrix metalloproteinases inhibitors in the treatment of arthritis. Current Opinions in Anti-inflammatory and Immunomodulatory Investigative Drugs 2000, 2, 16-25.
• Clark IM, Bigg HF, Rowan AD, Edwards DR, Mann DA, Bahr MJ, Cawston TE. Regulation of human TIMP-1 Gene Expression. In: Tissue Inhibitors of metalloproteinases in development and disease: proceedings of the Inhibitors of Metalloproteinases Conference. 2000, Banff, Canada: Harwood Academic Press.
• Shingleton WD, Ellis AJ, Rowan AD, Cawston TE. Retinoic acid combines with interleukin-1 to promote the degradation of collagen from bovine nasal cartilage: Matrix metalloproteinases-1 and -13 are involved in cartilage collagen breakdown. Journal of Cellular Biochemistry 2000, 79(4), 519-531.
• Shingleton WD, Ellis AJ, Rowan AD, Cawston TE. Retinoic acid combines with interleukin-1 to promote the degradation of collagen from bovine nasal cartilage: Matrix metalloproteinases-1 and-13 are involved in cartilage collagen breakdown. Journal of Cellular Biochemistry 2000, 79(4), 519-531.
• Hui W, Rowan AD, Cawston TE. Transforming growth factor-beta 1 blocks the release of collagen fragments from bovine nasal cartilage stimulated by oncostatin M in combination with IL-1 alpha. Cytokine 2000, 12(6), 765-769.
• Koshy PJT, Rowan AD, Life PF, Cawston TE. 96-well plate assays for measuring collagenase activity using ³H-acetylated collagen. Analytical Biochemistry 1999, 275(2), 202-207.
• Rowan A, Bataille V, MacKie R, Healy E, Bicknell D, Bodmer W, Tomlinson I. Somatic mutations in the Peutz-Jegners (LKB1/STKII) gene in sporadic malignant melanomas. Journal of Investigative Dermatology 1999, 112(4), 509-511.
• Cawston T, Billington C, Cleaver C, Elliott S, Hui W, Koshy P, Shingleton B, Rowan A. The regulation of MMPs and TIMPs in cartilage turnover. Annals of the New York Academy of Sciences 1999, 878, 120-129.
• Cawston T, Billington C, Cleaver C, Elliott S, Hui W, Koshy P, Shingleton B, Rowan A. The regulation of MMPs and TIMPs in cartilage turnover. In: Inhibition of Matrix Metalloproteinases Therapeutic Applications. 1999, Tampa, Florida: Wiley-Blackwell Publishing, Inc.
• Cawston T, Billington C, Cleaver C, Elliott S, Hui W, Koshy P, Shingleton B, Rowan A. The regulation of MMPs and TIMPs in cartilage turnover. In: Inhibition of Matrix Metalloproteinases: Therapeutic Applications. 1999, Tampa, Florida, USA: New York Academy of Sciences.
• Hodges, D.J., Reid, D.G., ROWAN, A.D., Clark, I.M., Cawston, T.E. Preparation of recombinant tissue inhibitor of metalloproteinases-1 (TIMP-1) in high yield and identification of a hydrophobic surface feature. European Journal Biochemistry 1998, 257, 562-569.
• Cawston TE, Rowan AD. Prevention of cartilage breakdown by matrix metalloproteinase inhibition - A realistic therapeutic target?. British Journal of Rheumatology 1998, 37(4), 353-356.
• Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJT, Rowan AD, Shingleton WD. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis & Rheumatism 1998, 41(10), 1760-1771.
• Clark IM, Rowan AD, Edwards DR, Bech-Hansen T, Mann DA, Bahr MJ, Cawston TE. Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochemical Journal 1997, 324(2), 611-617.